Hemato-oncology is a specialised area of cancer care focused on diagnosing and treating cancers of the blood, bone marrow, and lymphatic system. These include leukemias, lymphomas, multiple myeloma, myelodysplastic syndromes, myeloproliferative neoplasms, and other hematological malignancies.
Read MoreA bone marrow transplant is a type of hematopoietic stem cell transplant in which healthy blood-forming stem cells are collected from bone marrow and infused into the patient after conditioning treatment. The cells may come from the patient or a suitably matched donor. It may be considered for selected blood cancers based on the diagnosis, disease status, previous treatment, donor availability, overall health, and expected benefits and risks.
Read More
A stem cell transplant replaces blood-forming stem cells damaged by disease or intensive treatment. The stem cells are usually collected from the bloodstream and may come from the patient, called an autologous transplant, or from a related or unrelated donor, called an allogeneic transplant; donated umbilical cord blood may also be used. Suitability depends on the type and status of the disease, previous treatment, donor options, organ function, and overall health.
Read More
Chimeric antigen receptor T-cell therapy, or CAR T-cell therapy, is a personalised form of cellular immunotherapy. T cells are collected from the patient’s blood and modified in a specialised laboratory so that they can recognise a particular marker on abnormal cells. The modified cells are multiplied and infused back into the patient. CAR T-cell therapy is approved or available for selected blood cancers and clinical situations. Eligibility depends on the diagnosis, disease status, previous treatments, organ function, overall health, and whether an appropriate CAR T-cell product is available.
Read More
Chemotherapy uses medicines to destroy abnormal blood cells or stop them from growing. It may be given alone or combined with targeted therapy, immunotherapy, corticosteroids, radiation therapy, stem cell transplantation, or other treatments. Depending on the diagnosis, chemotherapy may be given in phases such as induction, consolidation, intensification, or maintenance. Some treatments are administered in hospital, while others may be given in a day-care setting or taken at home. The choice of medicine, dose, schedule, and duration depends on the specific disease and the patient’s health and response to treatment.
Targeted therapy acts on specific proteins, genes, enzymes, or signalling pathways that help abnormal blood cells grow and survive. Molecular, cytogenetic, immunophenotypic, or other biomarker testing may be used to determine whether a suitable treatment target is present. Some targeted therapies are taken orally, while others are given by injection or infusion. They may be used alone or with chemotherapy, immunotherapy, or other medicines. Although targeted treatments act on specific biological features, they can still affect healthy cells and cause side effects.
Immunotherapy helps the immune system recognise or act against abnormal cells. In hemato-oncology, treatment may include monoclonal antibodies, immune checkpoint inhibitors, immune-modulating medicines, or other immune-based approaches. The suitability of immunotherapy depends on the diagnosis, biomarker findings, previous treatment, and overall health. Some treatments can cause infusion reactions, infections, or immune-related effects and require careful monitoring.
How Hemato-Oncology Fits Into Your Overall Care Plan
Hemato-oncology care often begins with specialised testing to identify the exact type and biological characteristics of the disease. Because blood cancers that appear similar under a microscope may behave differently, flow cytometry, immunohistochemistry, cytogenetic studies, molecular testing, and other investigations can play an important role in classification and treatment planning.
For some patients, active surveillance may be appropriate. Others may need treatment promptly. Therapy may be intended to achieve remission, control the disease, reduce symptoms, prepare for transplantation, or maintain a previous response.
Stem cell transplant or CAR T-cell therapy may be considered after initial treatment, when the disease returns, or when it does not respond adequately to other therapies. Radiation therapy may be incorporated for selected lymphomas, plasma-cell tumours, disease affecting a specific site, symptom relief, or transplant conditioning.
The care plan is reviewed according to response assessments, test results, treatment tolerance, new clinical information, and the patient’s priorities.
What Patients Can Expect
Before Treatment
Your first consultation may include a review of symptoms, medical history, physical examination, blood counts, blood chemistry, pathology reports, imaging, bone marrow findings, and previous treatments.
Additional investigations may include:
Peripheral blood-smear examination
Bone marrow aspiration and biopsy
Flow cytometry or immunophenotyping
Cytogenetic or molecular testing
HLA typing when transplantation is being considered
Heart, lung, kidney, or liver assessments
Infection screening
Fertility assessment or preservation counselling when relevant
Your hemato-oncologist will discuss:
The diagnosis, subtype, and risk classification
Whether treatment is required immediately
The goals and available treatment options
Expected benefits, alternatives, and possible side effects
How treatment will be administered
The likely schedule and duration
Infection and bleeding precautions
Whether a central venous access device may be needed
Possible effects on fertility, work, travel, diet, and daily activities
Whether stem cell transplantation, CAR T-cell therapy, or a clinical trial may be appropriate
You will have an opportunity to ask questions and discuss your preferences before treatment begins.
During Treatment
Treatment may be given orally, by injection, through an intravenous infusion, or by another route. Some therapies are delivered in a day-care setting, while intensive treatments may require hospital admission.
Throughout treatment, your team may monitor blood-cell counts, organ function, disease-related symptoms, treatment response, and signs of infection, bleeding, or treatment reactions. Medicine levels or biomarkers may also be assessed when relevant. Supportive care may include blood or platelet transfusions, infection-prevention medicines, growth factors, hydration, and nutritional support.
Stem cell transplantation may involve collecting the patient’s stem cells or identifying a suitable donor, followed by conditioning treatment, stem cell infusion, and close monitoring while new blood cells develop. Infection precautions, transfusions, and supportive medicines may be required. After an allogeneic transplant, medicines are usually given to reduce the risk of graft-versus-host disease. Immune recovery may take several months or longer, making continued follow-up important.
CAR T-cell therapy generally involves collecting T-cells from the patient’s blood, modifying them in a specialised facility, administering lymphodepleting chemotherapy, and infusing the CAR T-cells. Close monitoring is required for complications such as cytokine release syndrome, neurological effects, infections, and prolonged reductions in blood-cell counts.
Report fever, breathing difficulty, unusual bleeding, confusion, severe weakness, or any other symptoms identified by your care team promptly, as complications can progress quickly when immunity is reduced.
After Treatment
At planned points during and after treatment, your doctor will evaluate the disease response. Depending on the diagnosis, this may involve blood tests, bone marrow examination, imaging, assessment of measurable or minimal residual disease, or other specialised investigations.
The next step may include further treatment, maintenance therapy, stem cell transplantation, CAR T-cell therapy, active surveillance, rehabilitation, or follow-up care. Long-term follow-up may address recurrence, infections, vaccination, organ health, bone health, fatigue, emotional well-being, fertility, and late effects of treatment.
